Intermountain takes its challenge of False Claims Act to the Supreme Court

FierceHealthcare | January 18, 2019

Intermountain Healthcare is trying to take its ongoing challenge of the False Claims Act (FCA) to the Supreme Court. The Salt Lake City-based health system has asked the court to review a decision by the 10th Circuit Court of Appeals, claiming the FCA violates the Appointments Clause of the Constitution. Specifically, they've pointed to whistleblower provisions which allow individuals to file fraud claims against health systems in the place of government officials. Intermountain described the FCA as a problem that unfairly plagues the industry the way it has been applied. Individuals file 600 such cases annually, the system said in its petition. "Due to the time- and cost-intensive discovery that most FCA actions require, defendants typically move to dismiss."

Spotlight

Blockchain technology alleviates the reliance on a centralized authority to certify information integrity and ownership, as well as mediate transactions and exchange of digital assets, while enabling secure and pseudo-anonymous transactions along with agreements directly between interacting parties. It possesses key properties, such as immutability, decentralization, and transparency, that potentially address pressing issues in healthcare, such as incomplete records at point of care and difficult access to patients’ own health information.


Other News
HEALTH TECHNOLOGY

Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area

Johnson & Johnson | September 21, 2022

Johnson & Johnson opened its San Francisco Bay Campus, a state-of-the-art Research & Development facility in the Bay Area, one of the world’s most established global hubs for innovation and entrepreneurship. The nearly 200,000 square-foot facility will house up to 400 employees, more than doubling the R&D presence of Johnson & Johnson in the Bay Area. The campus bridges key scientific and technological capabilities by co-locating Janssen R&D, Johnson & Johnson Innovation and Johnson & Johnson Technology. It will further integrate the Company into the Bay Area innovation ecosystem to strengthen and increase collaborations with innovators to accelerate growth. “Johnson & Johnson’s expanded presence in the Bay Area affirms our commitment to combining science and technology to deliver transformative healthcare solutions. On this campus, our talented teams will use their diverse experience and expertise to tackle society’s greatest health challenges to create a better future for patients.” Joaquin Duato, Chief Executive Officer, Johnson & Johnson The R&D focus at the new site spans Janssen’s therapeutic areas and key functions, including emerging science and technologies for gene and RNA therapies, novel treatments and approaches for retinal and infectious diseases, and advanced data science, including artificial intelligence and machine learning. Co-locating expertise at the site will enable the expansion of the Company’s world-class discovery engine and industry-leading pipeline. “Our new state-of-the-art science facility in the Bay Area will further strengthen our R&D capabilities and transform how we discover, develop and deliver innovative medicines faster and more efficiently. By integrating drug discovery, data science and digital health, we aim to accelerate the growth of our best-in-class portfolio and deliver better health outcomes for people worldwide,” said James Merson, Ph.D., Site Head, San Francisco Bay Campus and Global Therapeutic Area Head, Infectious Diseases, Janssen Research & Development, LLC. The Johnson & Johnson Innovation Center in California has facilitated investments and collaborations to accelerate early-stage healthcare innovation with academic and industry partners in the Bay Area and greater California ecosystem since 2014. The San Francisco Bay Campus, along with the Company’s JLABS @ South San Francisco, will continue to enable the Company to build strong relationships with entrepreneurs, scientists and investors to support and invest in highly differentiated innovations that extend and improve lives everywhere. Additionally, given the convergence of healthcare and technology in the region, the Company will increase its focus on the Johnson & Johnson Technology organization to enhance its ability to create innovative digital solutions to advance human health. Building on Johnson & Johnson’s long-standing commitment to use its expertise and resources to reduce the environmental footprint of its operations, the Bay Area hub is designed as a high-performance green campus, reinforcing the Company’s pledge to be responsible stewards in creating a healthy, more sustainable future. The aim is for the new site to receive Silver Leadership in Energy & Environmental Design (LEED) certification, the most widely used green building rating system in the world. About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. About Johnson & Johnson Technology Johnson & Johnson Technology solves big problems in healthcare through technology and digital innovation. Just as doctors use scalpels, we use data science, algorithms, artificial intelligence, robotics, and other digital solutions to transform patients’ lives. From guiding patients through treatment to accelerating vaccine development to enabling employees to work seamlessly from any location, our digital tools infuse our products with novelty, dexterity, and ease.

Read More

HEALTH TECHNOLOGY

Paradigm Oral Health Announces Acquisition by BlackRock Long Term Private Capital

Paradigm Oral Health | September 23, 2022

Paradigm Oral Health a leading oral surgery and digital dentistry platform announced that BlackRock Long Term Private Capital has entered into a definitive agreement to acquire a majority interest in the company from shareholders including InTandem Capital Partners. LTPC will partner with Paradigm’s executive leadership team, led by founder and CEO Dr. David Rallis, to support the company’s continued expansion and strategic growth plans. Founded in 2018, Paradigm has developed an industry-leading model designed to attract and retain best-in-class surgeons focused on delivering the highest quality of oral health care and dental implant surgery while fostering a medically-driven, patient-friendly culture of excellence. The company partners with leading oral surgery groups in markets across the United States, allowing them to maintain their unique brand identity while operating on the same platform. Paradigm’s proprietary practice management technology, Paragon, utilizes cutting-edge technology and data analytics to provide and store proprietary information and intelligence generated by the business, leading to enhanced performance as well as increased patient and provider satisfaction. Today, Paradigm and its team of over 100 surgeon partners provide patient care in 75 state-of-the-art facilities throughout the United States. “We are pleased to invest in Paradigm, which has established itself as an industry defining platform for the development and delivery of next-generation oral health solutions. Through its focus on providing superior clinical care, advanced technology, and continued training and education to its surgeon partners, the company is well positioned for long-term growth. We look forward to partnering with Dr. David Rallis and the entire Paradigm team.” Colm Lanigan, Head of BlackRock LTPC, Americas David Rallis, DDS, MD, and CEO of Paradigm Oral Health, commented, “Paradigm is advancing oral surgical outcomes and patient experience through a culture that places the needs of the patient first. At Paradigm, we validate our clinical performance through a proprietary data ecosystem and use data to reinforce our culture of excellence and accountability. Through innovation, and the rapid adoption of technology, we continue to set the standard for dental implant surgery. Aligning our company with world-class partners, first InTandem Capital and now BlackRock LTPC, has allowed Paradigm to emerge as a leader. We are humbled by the opportunity to partner with BlackRock LTPC, and excited to work with Colm Lanigan and his team as we continue to advance Paradigm as the global leader in oral surgery.” Elliot Cooperstone, Managing Partner of InTandem Capital Partners, Paradigm’s financial sponsor since 2019, commented, “InTandem Capital invests in healthcare companies that are local leaders with the ambition and potential to become a national powerhouse. Dr. David Rallis and the leadership team at Paradigm embraced our playbook for accelerated growth with amazing skill and dedication. Our deep trust in each other has allowed our partnership to flourish. My colleagues and I wish David and the Paradigm team the very best as they build on their well-deserved position as the country’s leading oral health company.” Paradigm is BlackRock LTPC’s sixth investment to date and its fourth investment in North America. Houlihan Lokey acted as financial advisor and Goodwin Procter acted as legal advisor to Paradigm. Simpson Thacher acted as legal advisor to Blackrock LTPC. About Paradigm Oral Health Paradigm Oral Health is the preeminent provider of oral surgery. Paradigm’s uniqueness comes from their ability to hire the most elite oral surgeons in the country and train them on their proprietary platform of excellence. Paradigm Oral Health continues to revolutionize and reinvent implant surgery through their ongoing technology and digital work-flow advancements. With a passion for excellence, Paradigm embraces every opportunity to meet the needs of their patients and referring dentists. About BlackRock LTPC BlackRock LTPC is an innovative private equity strategy focused on investing in high-quality businesses and value creation through active collaboration with management teams. The strategy's flexible duration and prudent approach to leverage preserve optionality for growth and help enable compounded capital appreciation. LTPC's team of 23 professionals are based in New York and London and invest across North America and Western Europe. LTPC is backed by BlackRock, Inc., which manages $320 billion in alternative investments and commitments on behalf of clients worldwide as of June 30, 2022. About InTandem Capital Partners InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. Its goal is to build excellent businesses of significant value working collaboratively with its management team partners. InTandem is comprised of former business executives and experienced investors, and is uniquely qualified to provide strategic, acquisition and operating expertise to help companies significantly increase their value over time. InTandem provides active support to the management of its portfolio companies directly and leverages its network of industry executives to augment its capabilities.

Read More

MEDICAL DEVICES

Asep Medical Holdings Inc. Announces Grant of Stock Options

ASEP Medical Holdings Inc | November 25, 2022

Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032. ABOUT ASEP MEDICAL HOLDINGS INC Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections. Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis. ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.

Read More

HEALTH TECHNOLOGY

Base Business Solutions and Uniphore Partner to Bring Emerging Technology to Vietnam’s CX Industry

Uniphore | September 12, 2022

Base Business Solutions a leading provider of cloud and hosted customer experience and contact center solutions in Vietnam announced it has entered into a strategic partnership with Uniphore, the leader in Conversational AI and Automation. Through this partnership, BaseBS will be well positioned to enhance customer experiences, improve employee performance, and better understand customer insights to achieve superior business outcomes. As part of the agreement, BaseBS will offer customers Conversational AI and Automation capabilities across their initiatives around self-service and assisted service channels. Uniphore’s X platform is an integrated conversational AI and automation platform that combines automatic speech recognition (ASR) including the Vietnamese language, natural language processing (NLP), robotic process automation (RPA), emotion AI and knowledge AI that enterprises need in today’s tech-savvy customer era. These technology components translate into specific offerings for customers in the form of chatbots, voice bots, conversational analytics for quality automation, and customer analysis and agent guidance in real-time. The partnership will have far-reaching benefits for customers, employees, and organizations that will impact not only how they do business today as they continue to adjust to the current global situation, but also in the long term. Benefits include Personalized automated resolutions for customers thus bringing in time to value through Uniphore’s U Self Serve product Contact center employee productivity and efficiency will see a boost through U-Assist, a Uniphore product that can guide agents in real-time with in-call alerts, next-best-action and reduce their after-call work Businesses will be able to make data-driven decisions with smarter conversational analytics. Through Uniphore’s U Analyze solution, businesses can transform CX by analysing conversations from across platforms including voice, email, and text to increase effectiveness with omnichannel support and an integrated view of conversations to discover customers' intent and sentiments “BaseBS is extremely pleased to partner with Uniphore on our journey to bring emerging technology such as Artificial Intelligence (AI), machine learning and automation to the CX industry in Vietnam. With Uniphore’s conversational AI and automation platform we will be better positioned to enable our customers to personalize conversations, enhance contact center employee productivity and use conversation insights for better decisions.” Mr. Pham Xuan Phuc, Vice President, Base Business Solutions “We are excited about the partnership with BaseBS as they look ahead to strengthen and offer more comprehensive CX solutions for contact centers in the local market,” said Mr. Gokul Gopalakrishnan, Senior Vice President & Business Head, Asia, Uniphore. “We see a natural synergy with BaseBS thereby creating strong joint value propositions, go-to-market strategies, and unmatched CX solutions for enterprises, and experiences for customers.” BaseBS is part of Uniphore’s Reseller partner program. The program provides partners with the necessary resources to leverage cutting-edge technology and enhance their portfolio and offerings resulting in increased revenue growth. Uniphore also launched the Unite App Alliance Partner Program, which enables value-driven collaboration and cross-selling for participating Independent Software Vendors (ISV) to have greater access to and involvement in shaping the direction and strategy of tomorrow’s conversational AI and automation, and supporting CX technology innovation. About Uniphore Uniphore is the global leader in Conversational Automation. Every day, billions of conversations take place across industries — customer service, sales, HR, education and more. Whether they are human to human, human to machine or machine to machine, conversations are at the heart of everything we do, and the new currency of the enterprise. At Uniphore, we believe companies that best understand and take action on those conversations will win. We have built the most comprehensive and powerful conversational automation platform that combines conversational AI, workflow automation and RPA (Robotic Process Automation) with a business user friendly UX in a single integrated platform to transform and democratize customer experiences across industries. Follow our blog and connect with us on LinkedIn, Twitter, Facebook, and Instagram. About Base Business Solutions Founded in 2005, BaseBS is one of the leading companies providing cloud and hosted customer experience and contact center solutions in Vietnam. BaseBS offers tailor-made CX solutions to hyper-scale and large enterprise clients that empower them to achieve customer service excellence and gain competitive advantages in the market. We are honored as Advanced Technology Partner of Cisco in implementing Call Center & Contact Center infrastructure. A combination of comprehensive industry expertise, a professional team and leading-edge technologies enables our clients to modernize their customer journey and maximize business productivity. Our portfolio is active in a wide range of business areas such as Banking & Finance, Insurance, Retail, Logistics, Hospitality, Medical & Healthcare, etc.

Read More

Spotlight

Blockchain technology alleviates the reliance on a centralized authority to certify information integrity and ownership, as well as mediate transactions and exchange of digital assets, while enabling secure and pseudo-anonymous transactions along with agreements directly between interacting parties. It possesses key properties, such as immutability, decentralization, and transparency, that potentially address pressing issues in healthcare, such as incomplete records at point of care and difficult access to patients’ own health information.

Resources